Abstract 240 Figure 2 Patients with a stage IIB-IV high-grade serous ovarian cancer who underwent neoadjuvant chemotherapy followed by interval debulking surgery with a systematic lymphadenectomy. A) Recurrence free survival (RFS) according to node status after neo-adjuvant chemotherapy ($p < 0.001$); B) Overall survival (OS) according to node status after neo-adjuvant chemotherapy ($p < 0.001$)

lymphadenectomy and no lymphadenectomy group concerning 2-year RFS (47.4% and 48.6%, $p = 0.87$, respectively) and 5-year OS (63.2% versus 58.6%, $p = 0.41$, respectively). Post-operative complications tended to be more frequent in the group with a lymphadenectomy (18.57 versus 31.58, $p = 0.09$). In the group of patients with lymphadenectomy, survival was significantly altered in patients with involved nodes (positive lymph nodes: 2-year RFS 42.5% and 5-year OS 49.4%, negative nodes: 2-year RFS 60.7% and 5-year OS 82.2%, $p = 0.03$ and $p < 0.001$, respectively).

Conclusion* Lymphadenectomy during IDS does not improve survival and increases post-operative complications.

241

IMPACT OF CO-MEDICATION ON SURVIVAL IN PATIENTS WITH OVARIAN CANCER – A ANALYSIS OF 4 PROSPECTIVE TRIALS OF THE AGO-OVAR AND ENGOT/ GCIG COLLABORATORS

¹D Denschlag*, ²F Heitz, ³J Pfisterer, ⁴D Tutschkow, ⁵W Meier, ²P Harter, ⁶P Wimberger, ⁷MR Mirza, ⁸I Ray-Coquard, ⁹G Scambia, ¹⁰JW Kim, ¹¹N Colombo, ¹²A Oaknin, ¹³J Sehoul, ¹⁴K Lindemann, ¹⁵A Floquet, ¹⁶M Eichbaum, ¹⁵S Spiegelberg, ¹³H Woonen, ²A Du Bois. ¹Hochtaunus-Klinken Bad Homburg, Gynecology, Bad Homburg, Germany; ²Klinikum Essen Mitte, Gynecologic Oncology; ³Gynecologic Oncology Center Kiel; ⁴University of Marburg, Center for Clinical Trials, Germany; ⁵University of Düsseldorf, Germany; ⁶University of Dresden, Gynecology, Germany; ⁷Copenhagen University Hospital, Department of Oncology, Copenhagen, Denmark; ⁸Centre Leon Berard, Université Claude Bernard Lyon Est, France; ⁹Università Cattolica del Sacro Cuore, Policlinico Gemelli, Rome, Italy; ¹⁰Seoul National University, Obstetrics and Gynecology, Seoul, Korea, Dem. People's Rep. Of; ¹¹European Institute of Oncology, Gynecologic Oncology, Milano, Italy; ¹²Vall d'Hebron University Hospital, Barcelona, Spain; ¹³Charité University Hospital Campus Virchow, Gynecologic Oncology, Germany; ¹⁴Oslo University Hospital Division of Cancer Medicine, Gynecologic Oncology, Oslo, Norway; ¹⁵Institut Bergonie, Bordeaux Cedex, France; ¹⁶Helios Dr. Horst Schmidt Kliniken, Gynecology, Wiesbaden, Germany

10.1136/ijgc-2021-ESGO.366

Introduction/Background* There is poor evidence from mostly retrospective series whether co-medication with metformin, statin or beta-blocker have an impact on survival in patients with primary ovarian cancer. The aim of this study was to investigate the association of these medications with survival.

Methodology Individual data from 3 prospective phase III randomized controlled trials (AGO-OVAR 11/ICON 7, 12, 16) and one phase II trial (AGO-OVAR 15) were pooled and analyzed. Patients were either classified as “ever-user” if the specific co-medication was documented at least once during the trial. In contrast, “never-users” served as controls.

Data were adjusted for potential confounders (age, FIGO stage, histology, residual tumor after surgery, ECOG performance status, BMI, Charlson Comorbidity Index and assigned treatment within the trial) in multivariate Cox regression analyses.

Result(s)* Overall, 2,857 patients were included in the analyses. “Ever-users” were: N=100 patients received metformin (3.5%), N=226 received statins (7.9%), and N=475 (16.6%) received beta-blockers (BB) (N=391 selective (sBB); N=84 non-selective (nsBB)) as co-medication.

There were no significant differences regarding the baseline characteristics (histology, FIGO stage, residual tumor after surgery, and chemotherapy-schedule) between “ever- and never-users” except that “ever-users” were significantly older and more obese, compared to controls.

Median progression-free (PFS) and overall survival (OS) for the entire cohort was 18.7 months and 60.1 months, respectively

Multivariate analyses for PFS and OS including age, BMI, Histology, FIGO stage, residual tumor after surgery, ECOG performance status and CCI revealed neither a significant impact of metformin on survival of “ever-users”, compared to “never-users” (PFS HR 0.94 95%-CI 0.69-1.29, $p = 0.7$; OS HR 0.82 95%-CI 0.58-1.17, $p = 0.28$), nor for statins (PFS HR 0.98 95%-CI 0.82-1.18, $p = 0.87$; OS HR 0.91 95%-CI

0.74-1.12, $p=0.37$), respectively. In contrast, “ever-users” of sBB had a significantly elevated risk for recurrence and death in multivariate analysis (PFS HR 1.22 95%-CI 1.05-1.41, $p=0.009$; OS HR 1.25 95%-CI 1.06-1.47, $p=0.009$).

Conclusion* In this large pooled analysis neither a co-medication with metformin nor with statins had a significant impact on survival in patients with primary ovarian cancer. In contrast, co-medication with a beta-blocker was associated with worse survival. Further studies are warranted to confirm this observation.

242

PARP-INHIBITORS BEYOND PROGRESSION: A NEW WAY TO MANAGE OLIGOMETASTATIC OVARIAN CANCER RECURRENCE

¹C Marchetti*, ¹E Palluzzi, ¹S Cappuccio, ¹G Avesani, ¹A Nardangeli, ^{1,2}G Scambia, ^{1,2}A Fagotti. ¹Fondazione Policlinico Agostino Gemelli-IRCCS, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Rome, Italy; ²Università Cattolica del Sacro Cuore, Rome, Italy

10.1136/ijgc-2021-ESGO.367

Introduction/Background* The benefit of surgery and maintenance treatment with parp inhibitors (PARPi) has been recently shown in ovarian cancer (OC) recurrence. Also, the efficacy and safety of stereotactic body radiotherapy (SBRT) is demonstrated in patients with metastatic, persistent, and recurrent OC. The management of oligometastatic progression (OMP) during PARPi maintenance is unclear and continuing the treatment beyond progression could be an option.

Methodology This is an observational, retrospective, single arm study. Patients affected by OC recurrence treated with PARPi

Abstract 242 Figure 1

in maintenance setting received surgery or SBRT, if OMP occurred. OMP was assessed by either CT scan or PET/CT scan, in case of isolated disease progression (one nodule) or discrete diffusion (up to three nodules in different locations) or progression in “sanctuary” site. Maintenance treatment was continued until extensive progression of disease. Primary objectives were: Progression Free Survival 1 (PFS1), defined as the time elapsed from the start of PARPi and OMP; post-progression-PFS (ppPFS), defined as the time elapsed from OMP and the last follow up (FU). Beyond-progression PFS (bpPFS), defined as the time elapsed from the start of PARPi and the definitive progression of disease or last FU (PFS1+ppPFS), and efficacy of surgery versus SBRT at OMP were secondary objectives.

Result(s)* From June 2017 to December 2020 186 OC patients were treated with PARPi maintenance at recurrence. Of these 24 (13%) developed OMP (58% lymphnodes, 17% peritoneal, 25% visceral disease). Median age was 51 years. Olaparib and Niraparib maintenance were administered to 9 (38%) and 15 (62%) patients, respectively. Median PFS1 was 23 months [Confidence Interval (CI) 95% 11 – 34]. When OMP occurred 9 (38%) and 15 (62%) pts were subjected to surgery and SBRT, respectively. Median ppPFS was 6 months (CI 95% 5 – 7). At the time of this publication 62.5% patients are still on treatment with PARPi beyond progression. **Conclusion*** OC patients, who have an OMP during PARPi maintenance at recurrence, may continue to benefit from PARPi treatment if combined with local treatment. Molecular assessment at oligometastatic and extensive progression could provide further information to define PARPi resistance mechanisms according to the type of disease progression.

Abstract 242 Table 1

	PARPi maintenance
	Nr. (%)
All patients	24
Median age (years) (range)	51 (35-67)
Histology	
Serous	24 (100)
PARPi	
Olaparib	9 (38)
Niraparib	15 (62)
BRCA status	
BRCA MT	10 (42)
BRCA WT	14 (58)
Therapy at oligometastatic progression	
Surgery	9 (38)
SBRT	15 (62)
Site of oligometastatic progression	
Lymphnode	14 (58)
Peritoneal	4 (17)
Parenchymal disease	6 (25)
PFS	
	Months
	(CI)
Median PFS1	23 months
	(CI 95% 11 – 34)
Median ppPFS	6 months
	(CI 95% 5 – 7)
Median bpPFS	29 months
	(CI 95% 17 – 40)

253

PFS OF ELDERLY OVARIAN CANCER PATIENTS MIGHT BE PREDICTED BY G-8 GERIATRIC SCREENING TOOL – RESULTS OF A RETROSPECTIVE COHORT STUDY

¹K Anic*, ¹S Birkert, ¹R Schwab, ¹MW Schmidt, ¹V Linz, ¹S Krajnak, ¹A-S Heimes, ¹M Schmidt, ²C Westphalen, ³EK Hartmann, ¹A Hasenburg, ¹M Battista. ¹University Medical Centre of the Johannes Gutenberg University Mainz, Department of Gynaecology and Obstetrics, Mainz, GERMANY; ²University Medical Centre of the Johannes Gutenberg University Mainz, Department of Geriatric Medicine, Mainz, GERMANY; ³University Medical Centre of the Johannes Gutenberg University Mainz, Department of Anesthesiology, Mainz, GERMANY

10.1136/ijgc-2021-ESGO.368

Introduction/Background* The aim of this study was to evaluate the impact of the preoperative global health status on the prognosis of patients with ovarian cancer (OC) older than 60 years, who received cytoreductive surgery.

Methodology G-8 geriatric screening tool (G-8 score), Lee Schonberg prognostic index, Eastern Cooperative Oncology Group (ECOG) performance status and Charlson Comorbidity Index (CCI) were determined retrospectively in a consecutive